NEW YORK--(BUSINESS WIRE)--Omrix Biopharmaceuticals, Inc. (“Omrix” or the “Company”) (NASDAQ: OMRI) announced today several key senior management changes that will further strengthen the Company’s growing presence in the biosurgery sector in the U.S.
